Literature DB >> 23241882

IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling.

Judith Hoge1, Isabell Yan, Nathalie Jänner, Valéa Schumacher, Athena Chalaris, Oliver M Steinmetz, Daniel R Engel, Jürgen Scheller, Stefan Rose-John, Hans-Willi Mittrücker.   

Abstract

The cytokine IL-6 plays a protective role in immune responses against bacterial infections. However, the mechanisms of IL-6-mediated protection are only partially understood. IL-6 can signal via the IL-6R complex composed of membrane-bound IL-6Rα (mIL-6Rα) and gp130. Owing to the restricted expression of mIL-6Rα, classical IL-6 signaling occurs only in a limited number of cells such as hepatocytes and certain leukocyte subsets. IL-6 also interacts with soluble IL-6Rα proteins and these IL-6/soluble IL-6Rα complexes can subsequently bind to membrane-bound gp130 proteins and induce signaling. Because gp130 is ubiquitously expressed, this IL-6 trans-signaling substantially increases the spectrum of cells responding to IL-6. In this study, we analyze the role of classical IL-6 signaling and IL-6 trans-signaling in the innate immune response of mice against Listeria monocytogenes infection. We demonstrate that L. monocytogenes infection causes profound systemic IL-6 production and rapid loss of IL-6Rα surface expression on neutrophils, inflammatory monocytes, and different lymphocyte subsets. IL-6-deficient mice or mice treated with neutralizing anti-IL-6 mAb displayed impaired control of L. monocytogenes infection accompanied by alterations in the expression of inflammatory cytokines and chemokines, as well as in the recruitment of inflammatory cells. In contrast, restricted blockade of IL-6 trans-signaling by application or transgenic expression of a soluble gp130 protein did not restrain the control of infection. In summary, our results demonstrate that IL-6Rα surface expression is highly dynamic during the innate response against L. monocytogenes and that the protective IL-6 function is dependent on classical IL-6 signaling via mIL-6Rα.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241882     DOI: 10.4049/jimmunol.1201044

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions.

Authors:  Andrew L Croxford; Susanne Karbach; Florian C Kurschus; Simone Wörtge; Alexei Nikolaev; Nir Yogev; Sabrina Klebow; Rebecca Schüler; Sonja Reissig; Carolin Piotrowski; Elke Brylla; Ingo Bechmann; Jürgen Scheller; Stefan Rose-John; F Thomas Wunderlich; Thomas Münzel; Esther von Stebut; Ari Waisman
Journal:  J Invest Dermatol       Date:  2013-09-25       Impact factor: 8.551

2.  IL-6 Trans-Signaling Drives Murine Crescentic GN.

Authors:  Gerald S Braun; Yoshikuni Nagayama; Yuichi Maruta; Felix Heymann; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; David J Salant; Ute Raffetseder; Stefan Rose-John; Tammo Ostendorf; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2015-06-03       Impact factor: 10.121

Review 3.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

Review 4.  IL-6 biology: implications for clinical targeting in rheumatic disease.

Authors:  Leonard H Calabrese; Stefan Rose-John
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 5.  Interleukin-6 Family Cytokines.

Authors:  Stefan Rose-John
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-02-01       Impact factor: 10.005

Review 6.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

Review 7.  IL-6 as a keystone cytokine in health and disease.

Authors:  Christopher A Hunter; Simon A Jones
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

Review 8.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

9.  CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.

Authors:  Chunyan Zhang; Hong Xin; Wang Zhang; Paul J Yazaki; Zhifang Zhang; Keith Le; Wenzhao Li; Heehyoung Lee; Larry Kwak; Stephen Forman; Richard Jove; Hua Yu
Journal:  Immunity       Date:  2016-04-19       Impact factor: 31.745

10.  Type I interferons regulate susceptibility to inflammation-induced preterm birth.

Authors:  Monica Cappelletti; Pietro Presicce; Matthew J Lawson; Vandana Chaturvedi; Traci E Stankiewicz; Simone Vanoni; Isaac Tw Harley; Jaclyn W McAlees; Daniel A Giles; Maria E Moreno-Fernandez; Cesar M Rueda; Paranth Senthamaraikannan; Xiaofei Sun; Rebekah Karns; Kasper Hoebe; Edith M Janssen; Christopher L Karp; David A Hildeman; Simon P Hogan; Suhas G Kallapur; Claire A Chougnet; Sing Sing Way; Senad Divanovic
Journal:  JCI Insight       Date:  2017-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.